Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
22.16
-0.66 (-2.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Castle Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory
April 27, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021
April 26, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population
April 23, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention
April 22, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress
April 16, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma
April 15, 2021
From
Castle Biosciences
Via
Business Wire
Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy
April 14, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma
April 13, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.